.jpeg)
2026-06-26 03:21:39
Belumosudil is an oral selective ROCK2 inhibitor indicated for the treatment of chronic graft-versus-host disease (cGVHD) in patients who have failed at least two prior systemic therapies. This article provides a comprehensive overview of its efficacy data, real-world patient experiences, side effect management, and steroid-sparing effects to help patients fully understand this treatment option.
2026-06-24 04:56:11
Olutasidenib is an oral selective IDH1 inhibitor approved for adult patients with relapsed or refractory acute myeloid leukemia harboring IDH1 mutations. This article covers its mechanism of action, indications, clinical efficacy data and global treatment options.
2026-06-24 04:39:21
Gilteritinib (brand name XOSPATA) is a second-generation, highly selective FLT3 inhibitor indicated for relapsed or refractory FLT3-mutated acute myeloid leukemia. This article provides a comprehensive review of its mechanism of action, key clinical data, global access options, adverse event management and cutting-edge research progress.
2026-06-17 07:33:39
This article outlines the main adverse reaction profiles of gilteritinib, a FLT3-targeted therapy, and analyzes its safety characteristics and clinical monitoring principles from the dimensions of hematologic toxicity, organ safety risks and special differentiation syndrome.
2026-06-16 04:42:47
This article analyzes the adverse reaction characteristics of idelalisib, a selective PI3Kδ inhibitor, describes its safety risks across digestive, respiratory, cutaneous, hematological and hepatic dimensions, and introduces internationally accepted clinical monitoring and management principles.
2026-06-10 06:54:08
Understand the impact of Revumenib on platelet counts in KMT2A-rearranged leukemia. Learn why normalization at 2 months is a positive prognostic sign and review dosing costs (~$850-$1150/box).
2026-06-03 02:44:01
This article provides an in-depth analysis of ponatinib, a third-generation BCR-ABL inhibitor, focusing on its unique mechanism to overcome the T315I resistance mutation, its pivotal clinical role, and safety management strategies, offering crucial insights for treating resistant chronic myeloid leukemia (CML).
2026-06-02 06:05:36
Tafasitamab is an Fc-enhanced monoclonal antibody targeting CD19, which works by activating the immune system to attack cancer cells. It is used in the treatment of certain relapsed or refractory B-cell lymphomas.
2026-05-29 07:39:18
A comprehensive guide on the dosing, administration, and adverse effect management of Tafasitamab combined with Lenalidomide for relapsed or refractory DLBCL.
2026-05-28 02:37:56
Pirtobrutinib (brand name Jaypirca) is the world's first approved non-covalent (reversible) BTK inhibitor, specifically designed to overcome resistance to traditional covalent BTK inhibitors. This article details its clinical application, dosage management, and safety monitoring strategies in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).
2026-05-28 01:55:16
Gilteritinib is a targeted therapy designed for specific genetic mutations.To ensure safety and efficacy,patients must take this medication under the strict supervision of a hematologist or oncologist.Close follow-up and individualized management are essential.In the event of severe adverse reactions,treatment interruption or dose adjustments may be required.
2026-05-27 06:26:35
Pirtobrutinib (Brand Name: Jaypirca) is a next-generation reversible BTK inhibitor offering a new lifeline for patients with relapsed or refractory Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL/SLL). This article details its mechanism against BTK resistance, clinical efficacy, and safety profile.
